Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.04 USD
Change Today +0.22 / 5.76%
Volume 4.4M
SGYP On Other Exchanges
Symbol
Exchange
NASDAQ GS
NASDAQ CM
As of 2:58 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

synergy pharmaceuticals inc (SGYP) Snapshot

Open
$3.76
Previous Close
$3.82
Day High
$4.40
Day Low
$3.75
52 Week High
03/26/14 - $5.88
52 Week Low
10/10/14 - $2.45
Market Cap
390.8M
Average Volume 10 Days
2.5M
EPS TTM
$-1.02
Shares Outstanding
96.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNERGY PHARMACEUTICALS INC (SGYP)

synergy pharmaceuticals inc (SGYP) Related Businessweek News

No Related Businessweek News Found

synergy pharmaceuticals inc (SGYP) Details

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

35 Employees
Last Reported Date: 03/16/15

synergy pharmaceuticals inc (SGYP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $680.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.9K
Chief Scientific Officer
Total Annual Compensation: $368.5K
Compensation as of Fiscal Year 2013.

synergy pharmaceuticals inc (SGYP) Key Developments

Synergy Pharmaceuticals, Inc. expected to report Fiscal Year 2014 results on March 26, 2015. This event was calculated by Capital IQ (Created on March 20, 2015).

Synergy Pharmaceuticals, Inc. expected to report Fiscal Year 2014 results on March 26, 2015. This event was calculated by Capital IQ (Created on March 20, 2015).

Synergy Pharmaceuticals, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and the Full Year Ended December 31, 2014; Plans to First New Drug Application with the FDA for Plecanatide to Treat CIC in Fourth Quarter of 2015

Synergy Pharmaceuticals, Inc. announced consolidated unaudited financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $27,591,000 against $19,357,000 a year ago. Net loss was $30,555,000 against $19,851,000 a year ago. Net loss per basic and diluted share was $0.32 against $0.22 a year ago. For the full year, the company reported loss from operations of $94,278,000 against $62,311,000 a year ago. Net loss was $95,708,000 against $62,124,000 a year ago. Net loss per basic and diluted share was $1.02 against $0.73 a year ago. Net cash used in operating activities was $89.1 million as compared to $52.6 million of cash used in operating activities during the twelve months ended December 31, 2013. The company announced that in the fourth quarter of 2015, it plans to file its first new drug application (NDA) with the FDA for plecanatide to treat CIC.

Synergy Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:25 PM

Synergy Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:25 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Gary S. Jacob, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGYP:US $4.04 USD +0.22

SGYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $301.81 USD +1.18
Almirall SA €16.56 EUR -0.13
Ironwood Pharmaceuticals Inc $15.29 USD +0.19
Sucampo Pharmaceuticals Inc $14.00 USD -2.84
View Industry Companies
 

Industry Analysis

SGYP

Industry Average

Valuation SGYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNERGY PHARMACEUTICALS INC, please visit www.synergypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.